ANDA 209287, held by Chartwell Rx. Palonosetron Hydrochloride.
As of Nov 16, 2026, ANDA 209287 (Palonosetron Hydrochloride), held by Chartwell Rx, was first approved by FDA on Sep 19, 2018, with 1 approved supplement and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Sep 19, 2018 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Palonosetron HydrochlorideEQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML) · injectable;intravenous | Palonosetron Hydrochloride | Rx |
| Jul 25, 2025 | Supplement 1Labeling · Standard review | Approved | None posted |
| Sep 19, 2018 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters